Bayers’ revenues have mounted by 14.6% to €9.18 bl, largely due to growth in its consumer health and high-tech materials divisions. Net income has dropped to €525 mln, down from €532 mln a year earlier. Q2 net earnings fell by 1.3% owing to lawsuits and writing down a cancer drug. Bayer has taken special charges of €255 mnl in the quarter, of which €123 mln related to litigation and €132 mln from a partial write-down on cancer drug Zevalin.
{{comment.DateTimeStampDisplay}}
{{comment.Comments}}